Sen-Jam Pharmaceutical, a New York-based innovative life sciences company, announced on Wednesday that it has signed a third strategic partnership with KVK-Tech, a US-based Specialty Pharmaceutical Manufacturing company.

Under the collaboration, KVK-Tech will be providing formulation and Chemistry, Manufacturing & Controls (CMC) for Sen-Jam's first injectable anti-inflammatory therapeutic, SJP-100.

The drug is the first injectable in its class and is an immunomodulator with a unique, dual mechanism of action. Sen-Jam says that its formulation can provide individualised, precision, drug delivery. It is claimed to reduce the rate at which inflammatory proteins are released into the body from the immune system, while also reducing intracellular inflammation.

Kiran Vepuri, KVK-Tech director of Business Development, said, 'We are thrilled with our flourishing partnership with Sen-Jam Pharmaceutical. This third agreement, and in particular, this asset SJP-100, is a testament to the shared values around delivering new solutions that can positively change the lives of billions of people worldwide'